MedTrace Logo

Intracoronary Stenting and Antithrombotic Regimen: Lesion Platelet Adhesion as Selective Target of Endovenous Revacept

NCT03312855 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 334

Last updated 2020-04-20

No results posted yet for this study

Summary

The main objective is to evaluate the efficacy and safety of treatment with 2 doses (80 and 160 mg) of Revacept versus placebo in patients with stable coronary artery disease undergoing PCI.

Conditions

  • Stable Coronary Artery Disease

Interventions

DRUG

Revacept 80 mg

single dose, intravenous application of 80 mg Revacept

DRUG

Revacept 160 mg

single dose, intravenous application of 180 mg Revacept

DRUG

Placebo

single dose, intravenous application of Placebo solution

Sponsors & Collaborators

  • Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)

    collaborator OTHER

  • AdvanceCor GmbH

    collaborator INDUSTRY

  • Technical University of Munich

    collaborator OTHER

  • German Federal Ministry of Education and Research

    collaborator OTHER_GOV

  • Deutsches Herzzentrum Muenchen

    lead OTHER

Principal Investigators

  • Adnan Kastrati, MD · Deutsches Herzzentrum München

  • Steffen Massberg, MD · Klinikum der Universität München

  • Stefanie Schuepke, MD · Deutsches Herzzentrum Muenchen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-20
Primary Completion
2020-02-29
Completion
2020-03-26

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03312855 on ClinicalTrials.gov